Mr. Paul Averback reports

NYMOX REPORTS NOTICE: CALIFORNIA COURT ISSUED A TEMPORARY RESTRAINING ORDER ENJOINING LANHAM, RILEY, CUTLER AND THEIR NEVADA COMPANY AFTER COURT HEARING IN SANTA ANA, CALIFORNIA, NOVEMBER 2, 2023

A United States court in Orange county, California, has ruled against the group of ex-employees and agents Lanham, Riley and Cutler, as well as their Nevada company. The Superior Court of the State of California, Orange county, ruled in favour of Nymox's application for a temporary restraining order and ordered Randall Lanham, Richard Cutler, Christopher Riley and their Nevada company from using, disclosing, relying on or otherwise making publicly available any Nymox attorney-client privileged information and to turn over or make available to Nymox any and all Nymox information and Nymox property in their possession, custody or control.

This is a positive step in Nymox's efforts to protect its shareholders from the defendants' numerous attempts, with financing by the AscellaHealth company, to essentially steal all of the company's assets. The court order also will ensure the return to the company of its corporate documents that the company's former general counsel, Mr. Lanham has refused to return, despite being ethically bound to do so. This also protects the company's shareholders by preventing the further disclosure and release of highly sensitive attorney-client privileged information that Mr. Lanham has publicly disclosed and used to benefit himself and harm the company and its shareholders.

Given this order, the company urges all shareholders to contact Nymox if they receive or have received communications from any of the above-mentioned individuals, including CRNSV, that they believe may contain Nymox attorney-client privileged information.

Nymox is pleased to have the support of the vast majority of its shareholders and to know that, despite many months and hundreds of thousands of dollars, the Riley-Lanham group and its co-conspirators have only managed to garner the support of a small group of shareholders. More good milestones to follow for your company.

Paul Averback MD, chief executive officer of Nymox, said: "We are extremely pleased that the California court has agreed with us and enjoined the defendants from using, disclosing, relying on or otherwise making publicly available highly sensitive privileged information. We again thank our long-term supporters and all team members and expert collaborators from many disciplines for their solid contributions and steady efforts involved in the ongoing process. We will continue to provide updates and communications to our valued supporters whenever appropriate."

About Nymox Pharmaceutical Corp.

Nymox is in the process of submitting applications for the approval to market the company's first-in-class drug, Nymozarfex, to treat the symptoms of benign prostatic hyperplasia (BPH). BPH is one of the most common conditions affecting middle aged and elderly men throughout the world. BPH can be devastating to men who suffer from the condition.

We seek Safe Harbor.